Tissue Regenix Group plc
TRX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £28,646 | £29,493 | £24,476 | £19,746 |
| % Growth | -2.9% | 20.5% | 24% | – |
| Cost of Goods Sold | £15,025 | £15,453 | £10,731 | £8,725 |
| Gross Profit | £13,621 | £14,040 | £9,140 | £5,632 |
| % Margin | 47.5% | 47.6% | 37.3% | 28.5% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £13,148 | £14,434 | £13,268 | £12,499 |
| SG&A Expenses | £13,148 | £14,434 | £10,752 | £8,615 |
| Sales & Mktg Exp. | £0 | £0 | -£2,516 | -£3,884 |
| Other Operating Expenses | £124 | £0 | £0 | £0 |
| Operating Expenses | £13,272 | £14,434 | £10,752 | £8,615 |
| Operating Income | £349 | -£394 | -£2,010 | -£4,378 |
| % Margin | 1.2% | -1.3% | -8.2% | -22.2% |
| Other Income/Exp. Net | -£913 | -£1,275 | -£818 | -£764 |
| Pre-Tax Income | -£564 | -£1,669 | -£2,828 | -£5,142 |
| Tax Expense | £289 | -£12 | -£232 | -£157 |
| Net Income | -£713 | -£1,713 | -£2,695 | -£4,792 |
| % Margin | -2.5% | -5.8% | -11% | -24.3% |
| EPS | -0.01 | -0.024 | -0.031 | -0.068 |
| % Growth | 58.4% | 21.9% | 54.3% | – |
| EPS Diluted | -0.01 | -0.024 | -0.031 | -0.068 |
| Weighted Avg Shares Out | 70,603 | 70,427 | 70,345 | 70,331 |
| Weighted Avg Shares Out Dil | 70,593 | 70,427 | 70,345 | 70,331 |
| Supplemental Information | – | – | – | – |
| Interest Income | £10 | -£137 | £6 | £2 |
| Interest Expense | £882 | £1,138 | £741 | £692 |
| Depreciation & Amortization | £1,046 | £977 | £971 | £988 |
| EBITDA | £1,364 | £446 | -£1,039 | -£3,035 |
| % Margin | 4.8% | 1.5% | -4.2% | -15.4% |